Core Viewpoint - Rongchang Biologics (09995) has seen a significant stock increase, attributed to positive developments in the treatment of urothelial carcinoma and strong financial performance [1] Group 1: Stock Performance - Rongchang Biologics' stock rose nearly 8%, with a current price of 96.8 HKD and a trading volume of 238 million HKD [1] Group 2: Industry Developments - The 2026 European Association of Urology (EAU) annual meeting is taking place in London from March 13 to 16, showcasing innovative applications of HER2-targeted antibody-drug conjugate (ADC) Vidisizumab in urothelial carcinoma treatment [1] - Multiple cutting-edge research results from China are being presented, covering the entire disease spectrum from early to late stages and from bladder cancer to upper urinary tract urothelial carcinoma, providing strong new evidence for precision and organ-preserving treatments [1] Group 3: Financial Performance - Rongchang Biologics recently released a performance report indicating a revenue of 3.251 billion RMB, a year-on-year increase of 89.36% [1] - The company reported a net profit attributable to shareholders of 709 million RMB, marking a turnaround from losses [1] - Revenue growth is primarily driven by increased sales of injectable Taitasip and Vidisizumab, along with significant technology licensing income from granting Vor Biopharma Inc. exclusive global development and commercialization rights for Taitasip outside Greater China [1]

Core Viewpoint - Rongchang Biopharma (09995) has seen a significant stock price increase, attributed to positive developments in its product pipeline and strong financial performance [1] Group 1: Stock Performance - Rongchang Biopharma's stock rose nearly 8%, with a current price of 96.8 HKD and a trading volume of 238 million HKD [1] Group 2: Industry Developments - The 2026 European Association of Urology (EAU) annual meeting is taking place in London from March 13 to 16, showcasing innovative applications of HER2-targeted antibody-drug conjugate (ADC) Vidisitamab in the treatment of urothelial carcinoma [1] - Multiple cutting-edge research results from China were presented, covering the entire disease spectrum from early to late stages, including bladder cancer and upper urinary tract urothelial carcinoma, providing strong new evidence for precision and organ-preserving treatments [1] Group 3: Financial Performance - Rongchang Biopharma reported a revenue of 3.251 billion RMB, a year-on-year increase of 89.36% [1] - The company achieved a net profit attributable to shareholders of 709 million RMB, marking a turnaround from losses [1] - Revenue growth is primarily driven by increased sales of injectable Taitasip and injectable Vidisitamab, along with significant technology licensing income from granting Vor Biopharma Inc. exclusive global development and commercialization rights outside Greater China [1]

Core Viewpoint - Rongchang Biopharma (09995) reported a significant increase in revenue and profitability for the fiscal year 2025, driven by higher sales of its injectable products and a substantial rise in technology licensing income [1] Financial Performance - The company achieved total revenue of RMB 3.251 billion, representing a year-on-year increase of 89.36% [1] - Net profit attributable to the parent company was RMB 709 million, marking a turnaround from a loss to profitability [1] - Basic earnings per share were RMB 1.29 [1] Revenue Drivers - The increase in revenue was primarily due to higher sales of injectable drugs, specifically Tai Tasi Pi and Vidi Si Tuo Monoclonal Antibody [1] - The company granted Vor Biopharma Inc. exclusive global development and commercialization rights for Tai Tasi Pi outside Greater China, leading to a significant increase in technology licensing income [1] Margin and Expenditure Outlook - Nomura's research report predicts that the company's gross margin will increase by 5.4 percentage points year-on-year to 94.4%, benefiting from improved drug margins and a higher proportion of high-margin collaborative income [1] - Operating expenses are expected to rise by 28% year-on-year to RMB 3.5 billion due to a significant increase in cash reserves, reversing last year's cost-saving trend [1] - Research and development expenses and sales costs are projected to be RMB 1.6 billion each, aimed at sponsoring new molecular research and clinical trials, as well as enhancing drug sales [1]

Core Viewpoint - Rongchang Biopharma (09995) reported a significant increase in revenue and profit for the fiscal year 2025, driven by strong sales of its injectable products and a notable rise in technology licensing income [1] Financial Performance - The company achieved total revenue of RMB 3.251 billion, representing a year-on-year increase of 89.36% [1] - Net profit attributable to the parent company was RMB 709 million, marking a turnaround from a loss to profitability [1] - Basic earnings per share reached RMB 1.29 [1] Revenue Drivers - The increase in revenue was primarily due to higher sales of injectable products, specifically Tai Taisip and Vidisitamab [1] - The company granted Vor Biopharma Inc. exclusive global development and commercialization rights for Tai Taisip outside Greater China, leading to a substantial increase in technology licensing income [1] Margin and Expenses Outlook - Nomura's report predicts that the company's gross margin will rise by 5.4 percentage points year-on-year to 94.4%, benefiting from improved drug margins and a higher proportion of high-margin collaborative income [1] - Operating expenses are expected to increase by 28% year-on-year to RMB 3.5 billion due to a significant rise in cash reserves, reversing last year's cost-saving trend [1] - Research and development expenses and sales costs are projected to be RMB 1.6 billion each, aimed at sponsoring new molecular research and clinical trials, as well as enhancing drug sales [1]

Performance Summary - Xinyi Solar (00968.HK) reported a revenue of 20.861 billion yuan for 2025, a decrease of 4.8% year-on-year, with a net profit of 844.5 million yuan, down 16.2%, primarily due to a decline in average selling prices of solar glass products [2] - Zhongxin Innovation (03931.HK) expects a net profit of 2.025 billion to 2.193 billion yuan for 2025, an increase of approximately 140% to 160% compared to the previous year, driven by high growth in leading technology products across passenger, commercial, and energy storage sectors [2] - Rongchang Bio (09995.HK) anticipates a revenue of 3.251 billion yuan for 2025, an increase of 89.36% year-on-year, with a net profit of 709 million yuan, turning profitable due to increased sales of Tislelizumab and injection-use Vedolizumab [2] - Xinyi Energy (03868.HK) expects a revenue of 2.453 billion yuan for 2025, a slight increase of 0.53%, with a net profit of 1.011 billion yuan, up 27.79% [2] - Sihang Property (00083.HK) reported a revenue of 5.185 billion HKD for the six months ending December 31, 2025, an increase of 34.54%, while net profit decreased by 15.77% to 1.533 billion HKD [3] - Haohai Biological Technology (06826.HK) expects a revenue of approximately 2.473 billion yuan for 2025, a decrease of 8.33%, with a net profit of about 251 million yuan, down 40.3% [4] - Chunli Medical (01858.HK) anticipates a total revenue of approximately 1.044 billion yuan for 2025, a year-on-year increase of 29.52%, with a net profit of 272 million yuan, up 117.72% [5] - Baosheng International (03813.HK) issued a profit warning, expecting a net profit of approximately 211 million yuan for 2025, a decrease of about 57.1% [6] - Chip Intelligence Holdings (02166.HK) expects a net profit of approximately 140 million to 170 million HKD for 2025, an increase of about 40% to 70%, benefiting from the booming AI technology and increasing market demand [6] - Fengcai Technology (01304.HK) anticipates a total revenue of approximately 774 million yuan for 2025, a year-on-year increase of 28.91%, with a net profit of about 227 million yuan, up 1.92% [6] - Huayou Energy (01251.HK) issued a profit warning, expecting a loss of approximately 100 million to 150 million HKD for the 2025 fiscal year [7] - Zhoneng Group (00131.HK) reported a revenue of 272 million HKD for the six months ending December 31, 2025, an increase of 250.64%, with a net profit of 180 million HKD, turning profitable [8] - Fudan Zhangjiang (01349.HK) expects a revenue of approximately 686 million yuan for 2025, a decrease of 3.33%, with a net loss of approximately 157 million yuan, turning from profit to loss [9] Company News - Bay Area Development (00737.HK) reported that the total toll revenue for January from the Guangzhou-Shenzhen Expressway, Guangzhou-Zhuhai West Line Expressway, and the Shenzhen section of the Yangtze River Expressway was approximately 241 million, 105 million, and 75.169 million yuan, respectively, representing year-on-year growth of 15%, 17%, and 19% [10] - LeCang Logistics (02490.HK) plans to acquire two large container ships [10] - Innovent Biologics (01801) received approval for Jebatuzumab (Pimobendan) in China for the indication of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma [11] Buyback Activities - Xiaomi Group-W (01810.HK) repurchased 2.8582 million shares for a total of approximately 99.9973 million HKD, with a repurchase price ranging from 34.92 to 35.04 HKD per share [12] - Geely Automobile (00175.HK) repurchased 3.673 million shares for approximately 59.4327 million HKD, with a repurchase price between 16.1 and 16.3 HKD [13] - Miniso Group (09896.HK) repurchased approximately 0.0526 million shares for about 1.8893 million HKD, with a repurchase price ranging from 35.64 to 36.34 HKD [14] - NetEase Cloud Music (09899.HK) repurchased approximately 0.09715 million shares for about 14.9959 million HKD, with an average repurchase price of 154.36 HKD [14]

Core Viewpoint - Rongchang Biopharma (09995) reported a significant increase in revenue and profitability for the fiscal year 2025, indicating strong business performance driven by product sales and licensing agreements [1] Financial Performance - The company achieved total revenue of RMB 3.251 billion, representing a year-on-year increase of 89.36% [1] - Net profit attributable to the parent company was RMB 709 million, marking a turnaround from a loss to profitability [1] - Basic earnings per share were RMB 1.29 [1] Revenue Drivers - The increase in revenue was primarily due to higher sales volumes of injectable Tisotumab Vedotin and injectable Vedolizumab, contributing to increased sales revenue [1] - Additionally, the company granted Vor Biopharma Inc. exclusive global development and commercialization rights for Tisotumab Vedotin outside Greater China, leading to a substantial increase in licensing revenue [1]

Core Viewpoint - Rongchang Biopharma (09995) reported a significant increase in revenue and profitability for the fiscal year 2025, indicating strong business performance driven by product sales and licensing agreements [1] Financial Performance - The company achieved total operating revenue of RMB 3.251 billion, representing a year-on-year increase of 89.36% [1] - Net profit attributable to the parent company was RMB 709 million, marking a turnaround from a loss to profitability [1] - Basic earnings per share were RMB 1.29 [1] Revenue Drivers - The increase in operating revenue was primarily due to higher sales volumes of injectable Tisotumab Vedotin and injectable Vidatox, leading to increased sales revenue [1] - Additionally, the company granted Vor Biopharma Inc. exclusive global development and commercialization rights for Tisotumab Vedotin outside Greater China, resulting in a substantial increase in licensing revenue [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of SHR-A2102, indicating progress in its drug development pipeline [1] Group 1: Drug Information - Drug Name: SHR-A2102 [1] - Dosage Form: Injection [1] - Application Type: Clinical trial [1] - Acceptance Numbers: CXSL2500879, CXSL2500881 [1] Group 2: Clinical Trial Details - The approval allows for two clinical trials: 1. A trial combining SHR-A2102 with Vedolizumab in patients with advanced solid tumors [1] 2. A trial assessing the safety, tolerability, and efficacy of SHR-A2102 combined with Atezolizumab or other PD-(L)1 inhibitors in patients with locally advanced or metastatic esophageal cancer [1] - The trials are categorized as multicenter, open-label, Phase I/II studies [1] Group 3: Regulatory Approval - The clinical trial applications were reviewed and approved based on the requirements of the Drug Administration Law of the People's Republic of China [1] - The approval was granted for applications received on October 13 and 14, 2025 [1]

Core Viewpoint - Heng Rui Medicine's subsidiary has received approval from the National Medical Products Administration for clinical trials of SHR-A2102, a targeted antibody-drug conjugate aimed at treating advanced solid tumors and esophageal cancer [1] Group 1: Clinical Trials - The company will conduct two clinical trials for SHR-A2102, one in combination with Vedolizumab for advanced solid tumors and another with Atezolizumab or other PD-(L)1 drugs for locally advanced or metastatic esophageal cancer [1] - The trials will assess the safety, tolerability, and efficacy of SHR-A2102 in a multicenter, open-label Phase I/II study [1] Group 2: Product Details - SHR-A2102 is an antibody-drug conjugate (ADC) targeting Nectin-4, with its active payload being a topoisomerase I inhibitor (TOP1i) [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of its drug SHR-A2102, indicating progress in its oncology pipeline and potential market entry for a new targeted therapy [1] Group 1: Clinical Trials - The company’s subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., and Shanghai Heng Rui Medicine Co., Ltd. have been authorized to conduct two clinical trials for SHR-A2102 [1] - The first trial will evaluate SHR-A2102 in combination with Vedolizumab for advanced solid tumors [1] - The second trial will assess SHR-A2102 in combination with Atezolizumab or other PD-(L)1 inhibitors for locally advanced or metastatic esophageal cancer in a multicenter, open-label Phase IB/II study [1] Group 2: Product Details - SHR-A2102 is a targeted antibody-drug conjugate (ADC) that targets Nectin-4, with an effective payload of topoisomerase I inhibitor (TOP1i) [1] - Currently, there is one similar product, Enfortumab vedotin (brand name: Padcev), which has been approved and is projected to generate global sales of approximately $1.949 billion in 2024 [1] Group 3: Investment and Development - The total investment in the SHR-A2102 development project has reached approximately 248.22 million yuan [1]